Camizestrant vs Imlunestrant

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Camizestrant · Etcamah

Marketed by AstraZeneca

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Reliable signal

NCT04964934 · Phase 3 · active, not recruiting

This was a randomized, triple-blinded, placebo-controlled Phase III trial with an active comparator (continued aromatase inhibitor) in 315 patients, using progression-free survival (a hard clinical endpoint) as the primary measure. The result, reported via an external source since CT.gov has not yet posted results, showed a clear and highly statistically significant benefit for camizestrant (median PFS 16.0 vs 9.2 months, HR 0.44, p<0.00001), meeting the primary endpoint in the favorable direction.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2027 · NCT04644068 (registry estimate)

Reported efficacy

Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) (From randomization until the earlier of the progression event or death (approximately 2 years)): SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 (met)

Result source: NCT04964934

Imlunestrant · Inluriyo

Marketed by Eli Lilly

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT04975308 · Phase 3 · active, not recruiting

EMBER-3 randomised 874 patients with ER-positive, HER2-negative advanced breast cancer in an open-label design, with three registered primary PFS comparisons. Imlunestrant beat standard endocrine therapy in patients with ESR1 mutations (HR 0.617, p=0.0008) but not in all patients (HR 0.867, p=0.1158), and the combination with abemaciclib beat imlunestrant alone (HR 0.569, p<0.0001). The result is mixed across the primaries and the open-label design keeps the grade at moderate.

Next expected readout: October 2028 · NCT07905001 (registry estimate)

Reported efficacy

Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)); Investigator-assessed PFS (Between Arm C and Arm A) (Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)); Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)): Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001 (mixed)

Result source: NCT04975308

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCamizestrantImlunestrant
PFS, median—Trial running · NCT077174505.5 vs 5.5vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
7 other results
OS, median—Trial running · NCT07717450—Trial running · NCT04975308
ORR—Trial running · NCT0771745010.3% vs 6.4%vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
3 other results
Clinical benefit rate—Trial running · NCT0771745046.8% vs 45.5%vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
3 other results

PFS, median

Camizestrant
—Trial running · NCT07717450
Imlunestrant
5.5 vs 5.5vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
7 other results

OS, median

Camizestrant
—Trial running · NCT07717450
Imlunestrant
—Trial running · NCT04975308

ORR

Camizestrant
—Trial running · NCT07717450
Imlunestrant
10.3% vs 6.4%vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
3 other results

Clinical benefit rate

Camizestrant
—Trial running · NCT07717450
Imlunestrant
46.8% vs 45.5%vs Investigator's Choice of Endocrine Therapyn 331NCT04975308
3 other results
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Camizestrant
SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 NCT04964934 · Phase 3 · design grade: strong · publication or press release
Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81) NCT04588298 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Camizestrant: 4 of 4 rows · Imlunestrant: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCamizestrantImlunestrant
Dropout rate
3.3%75 mga
NCT04588298 · Phase 2
show 4 more results
3.3%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
25.7%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
45.1%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Discontinued due to AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
3%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
5.6%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Serious AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
0%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
14.1%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
20.2%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Most frequent reported AEs
75 mga
nausea 13.3%
fatigue 6.7%
headache 6.7%
NCT04588298 · Phase 2
show 4 more results
75 mg
visual impairment 20%
headache 10%
photopsia 10%
NCT04588298 · Phase 2
300 mg
hypertension 23.1%
visual impairment 23.1%
photopsia 15.4%
NCT04588298 · Phase 2
150 mg
visual impairment 15.2%
diplopia 12.1%
photopsia 12.1%
NCT04588298 · Phase 2
150 mg
visual impairment 24.1%
diplopia 17.2%
hypertension 13.8%
NCT04588298 · Phase 2
diarrhoea 21.7%
nausea 18%
arthralgia 15.3%
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
diarrhoea 86.5%
nausea 50%
anaemia 43.8%
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Imlunestrant

PFS 5.55 vs 5.52 Investigator's Choice of Endocrine Therapy months
time to event · months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 3 more results
5.49 vs 3.84 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.23 vs 7.36 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
7.43 vs 5.49 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
PFS 9.36 months
time to event · months
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 3 more results
5.49 months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
14.52 months
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.23 months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 10.3% (n=331) vs 6.4% (n=330) Investigator's Choice of Endocrine Therapy
responder rate · % of participants
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
11.6% (n=138) vs 5.9% (n=118) Investigator's Choice of Endocrine Therapy
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 11.1 vs 7.39 Investigator's Choice of Endocrine Therapy months
time to event · months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
10.02 vs 5.59 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 46.8% (n=331) vs 45.5% (n=330) Investigator's Choice of Endocrine Therapy
responder rate · % of participants
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
46.4% (n=138) vs 36.4% (n=118) Investigator's Choice of Endocrine Therapy
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 21.1% (n=213)
responder rate · % of participants
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
9.4% (n=213)
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 11.07 months
time to event · months
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
10.02 months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 62.9% (n=213)
responder rate · % of participants
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
44.1% (n=213)
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Breast Cancer

Shared mechanism: Estrogen receptor · full Breast Cancer pipeline

Camizestrant · Etcamah

Marketed by AstraZeneca

Approved in Breast Cancersmall molecule
Reliable signal

NCT04964934 · Phase 3 · active, not recruiting

This was a randomized, triple-blinded, placebo-controlled Phase III trial with an active comparator (continued aromatase inhibitor) in 315 patients, using progression-free survival (a hard clinical endpoint) as the primary measure. The result, reported via an external source since CT.gov has not yet posted results, showed a clear and highly statistically significant benefit for camizestrant (median PFS 16.0 vs 9.2 months, HR 0.44, p<0.00001), meeting the primary endpoint in the favorable direction.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: April 2027 · NCT05774951 (registry estimate)

Reported efficacy

Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) (From randomization until the earlier of the progression event or death (approximately 2 years)): SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 (met)

Result source: NCT04964934

Imlunestrant · Inluriyo

Marketed by Eli Lilly

Approved in Breast Cancersmall molecule
Partial signal

NCT04975308 · Phase 3 · active, not recruiting

EMBER-3 randomised 874 patients with ER-positive, HER2-negative advanced breast cancer in an open-label design, with three registered primary PFS comparisons. Imlunestrant beat standard endocrine therapy in patients with ESR1 mutations (HR 0.617, p=0.0008) but not in all patients (HR 0.867, p=0.1158), and the combination with abemaciclib beat imlunestrant alone (HR 0.569, p<0.0001). The result is mixed across the primaries and the open-label design keeps the grade at moderate.

Next expected readout: October 2027 · NCT05514054 (registry estimate)

Reported efficacy

Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)); Investigator-assessed PFS (Between Arm C and Arm A) (Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)); Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B) (Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)): Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001 (mixed)

Result source: NCT04975308

Results for Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Camizestrant
SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001 NCT04964934 · Phase 3 · design grade: strong · publication or press release
Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81) NCT04588298 · Phase 2 · design grade: weak · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

Coverage. Camizestrant: 4 of 4 rows · Imlunestrant: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCamizestrantImlunestrant
Dropout rate
3.3%75 mga
NCT04588298 · Phase 2
show 4 more results
3.3%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
25.7%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
45.1%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Discontinued due to AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
7.7%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
6.9%150 mg
NCT04588298 · Phase 2
3%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
5.6%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Serious AEs
0%75 mga
NCT04588298 · Phase 2
show 4 more results
0%75 mg
NCT04588298 · Phase 2
0%300 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
0%150 mg
NCT04588298 · Phase 2
14.1%Arm A: Imlunestrant
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
20.2%Arm C: Imlunestrant + Abemaciclib
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Most frequent reported AEs
75 mga
nausea 13.3%
fatigue 6.7%
headache 6.7%
NCT04588298 · Phase 2
show 4 more results
75 mg
visual impairment 20%
headache 10%
photopsia 10%
NCT04588298 · Phase 2
300 mg
hypertension 23.1%
visual impairment 23.1%
photopsia 15.4%
NCT04588298 · Phase 2
150 mg
visual impairment 15.2%
diplopia 12.1%
photopsia 12.1%
NCT04588298 · Phase 2
150 mg
visual impairment 24.1%
diplopia 17.2%
hypertension 13.8%
NCT04588298 · Phase 2
diarrhoea 21.7%
nausea 18%
arthralgia 15.3%
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
diarrhoea 86.5%
nausea 50%
anaemia 43.8%
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Imlunestrant

PFS 5.55 vs 5.52 Investigator's Choice of Endocrine Therapy months
time to event · months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 3 more results
5.49 vs 3.84 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.23 vs 7.36 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
7.43 vs 5.49 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
PFS 9.36 months
time to event · months
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 3 more results
5.49 months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
14.52 months
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.23 months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 10.3% (n=331) vs 6.4% (n=330) Investigator's Choice of Endocrine Therapy
responder rate · % of participants
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
11.6% (n=138) vs 5.9% (n=118) Investigator's Choice of Endocrine Therapy
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 11.1 vs 7.39 Investigator's Choice of Endocrine Therapy months
time to event · months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
10.02 vs 5.59 Investigator's Choice of Endocrine Therapy months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 46.8% (n=331) vs 45.5% (n=330) Investigator's Choice of Endocrine Therapy
responder rate · % of participants
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
46.4% (n=138) vs 36.4% (n=118) Investigator's Choice of Endocrine Therapy
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
ORR 21.1% (n=213)
responder rate · % of participants
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
9.4% (n=213)
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 11.07 months
time to event · months
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
10.02 months
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Clinical Benefit 62.9% (n=213)
responder rate · % of participants
No placebo or comparator arm
NCT04975308 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
44.1% (n=213)
NCT04975308 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camizestrant's landscape · Imlunestrant's landscape